Healthcare · Biotechnology
Price
$5.35
Market Cap
$347.9M
Employees
30
Beta
0.03
Avg Volume
793,869
CEO
Sandeep C. Kulkarni
Business Description
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Business History
Price Overview
Last updated: Jun 27, 2026 8:01am (just now)$5.35
+0.81 (+17.84%)
Day Range
$4.47 – $5.44
52-Week Range
$1.00 – $7.44
50-Day MA
$4.52
200-Day MA
$4.70
Volume
8,153,625.00
Analyst Price Targets
Low
$15.00
Consensus
$15.00
High
$15.00
(4 analysts)
Share Structure
Outstanding
65,021,979.00
Float
36,143,856.00
Free Float
55.6%
Normal free float
— 55.6% of shares trade freely, ~44.4% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-5.05
Stock Price: $5.35
EPS (Diluted): -1.06
EPS (Diluted): -1.06
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.86
Stock Price: $5.35
Total Equity: $101.54M
Shares: 94,160,138
Total Equity: $101.54M
Shares: 94,160,138
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.62
Market Cap: $347.87M
Total Debt: $0.00
Cash: $109.41M
EBITDA: -$68.60M
Total Debt: $0.00
Cash: $109.41M
EBITDA: -$68.60M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$384.0M
Market Cap: $347.87M
Total Debt: $0.00
Cash: $109.41M
Total Debt: $0.00
Cash: $109.41M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $5.35
Revenue: $0.00
Shares: 94,160,138
Revenue: $0.00
Shares: 94,160,138
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$75.25M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$68.65M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-54.6%
Net Income: -$68.65M
Total Equity: $101.54M
Total Equity: $101.54M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-37.6%
Operating Income: -$75.25M
Tax Rate: 0.0%
Equity: $101.54M
Total Debt: $0.00
Cash: $109.41M
Tax Rate: 0.0%
Equity: $101.54M
Total Debt: $0.00
Cash: $109.41M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
9.05
Current Assets: $112.31M
Current Liabilities: $12.41M
Current Liabilities: $12.41M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $101.54M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $101.54M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 94,160,138
Shares: 94,160,138
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.08
Total Equity: $101.54M
Shares: 94,160,138
Shares: 94,160,138
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.69
Operating CF: -$64.82M
CapEx: -$113,000
Shares: 94,160,138
CapEx: -$113,000
Shares: 94,160,138
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $5.35
Stock Price: $5.35
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$68.65M
Net Income: -$68.65M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ZURA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 2:23am (5h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $1.1M | $27.2M | $62.6M | $55.2M | $75.2M |
| Operating Income | -$1.1M | -$27.2M | -$62.6M | -$55.2M | -$75.2M |
| Net Income | $8.4M | -$25.7M | -$60.4M | -$52.4M | -$68.7M |
| EBITDA | $8.4M | -$27.3M | -$60.6M | -$52.4M | -$68.6M |
| EPS | $0.40 | $0.21 | $-2.09 | $-0.60 | $-1.06 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 2:23am (5h ago)| Metric | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $729,223 | $1.6M | $99.8M | $176.5M | $109.4M |
| Total Current Assets | $1.2M | $1.8M | $100.8M | $178.7M | $112.3M |
| Total Assets | $140.6M | $5.3M | $100.8M | $179.5M | $113.9M |
| Current Liabilities | $272,292 | $14.8M | $20.3M | $19.5M | $12.4M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.4M | $27.3M | $21.3M | $19.5M | $12.4M |
| Total Equity | $130.2M | -$32.1M | $59.3M | $146.8M | $101.5M |
| Retained Earnings | -$9.2M | -$32.1M | -$103.5M | -$155.9M | -$224.5M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 2:23am (5h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M | -$1.2M | -$15.1M | -$28.1M | -$64.8M |
| Capital Expenditure | $-4 | -$12.0M | -$8.0M | $-75,000 | $-113,000 |
| Free Cash Flow | -$1.1M | -$13.2M | -$23.1M | -$28.2M | -$64.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $729,223 | $1.6M | $98.2M | $76.7M | -$67.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 2:23am (5h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$10.7M $10.7M – $10.7M
|
$8.3M $8.3M – $8.3M
|
$16.7M $16.7M – $16.7M
|
$171.7M $171.7M – $171.7M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$86.6M -$91.0M – -$24.0M
|
-$90.9M -$117.7M – -$64.0M
|
-$101.7M -$101.7M – -$101.7M
|
-$71.6M -$71.6M – -$71.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 2:23am (5h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -2,387.4% | -130.6% | +11.9% | -36.3% |
| Net Income Growth | -405.8% | -134.5% | +13.2% | -31.0% |
| EBITDA Growth | -424.7% | -121.6% | +13.5% | -30.9% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 2:23am (5h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-17 | Mathew Marlyn Teresa | 0.00 | $0.00 | $0 | |
| 2026-04-17 | Mathew Marlyn Teresa | 11,133.00 | $0.00 | $0 | |
| 2026-04-17 | Mathew Marlyn Teresa | 90,000.00 | $3.38 | $304,200 | |
| 2026-04-17 | Mathew Marlyn Teresa | 81,150.00 | $1.20 | $97,380 | |
| 2026-04-17 | Mathew Marlyn Teresa | 66,220.00 | $6.03 | $399,307 | |
| 2026-06-17 | Jarrett Jennifer | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-06-17 | Thiara Parvinder | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-06-17 | Schoch Steven J | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-06-17 | Nirula Ajay | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-06-17 | Munshi Amit | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-06-17 | Eisner Mark | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-06-17 | Becker Daniel J. | A-Award | 51,000.00 | $3.62 | $184,620 |
| 2026-04-01 | Whale Gary | A-Award | 263,000.00 | $6.03 | $1.6M |
| 2026-04-01 | Nistala Kiran | A-Award | 340,900.00 | $6.03 | $2.1M |
| 2026-04-01 | Hyllengren Eric J | A-Award | 340,900.00 | $6.03 | $2.1M |
| 2026-04-01 | Davis Kim | A-Award | 425,700.00 | $6.03 | $2.6M |
| 2026-04-01 | Kulkarni Sandeep Chidambar | A-Award | 894,000.00 | $6.03 | $5.4M |
| 2026-02-21 | Nirula Ajay | A-Award | 37,812.00 | $6.53 | $246,912 |
| 2026-02-21 | Nirula Ajay | 0.00 | $0.00 | $0 | |
| 2026-02-26 | AI Biotechnology LLC | P-Purchase | 2,000,000.00 | $6.25 | $12.5M |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ZURA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ZURA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30